Study guide
1.2 Respiratory Failure and ARDS Pathophysiology
Board Certified Critical Care Pharmacist Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pathophysiology and Recognition of Critical Illness
1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness
2 Chapter 2: Medical Devices and Circulatory Support
2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care
3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management
3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation
4 Chapter 4: Vasoactive and Inotropic Therapy in Shock
4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock
5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)
5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness
6 Chapter 6: Cardiovascular Emergencies
6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias
7 Chapter 7: Pulmonary and Infectious Diseases in the ICU
7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU
8 Chapter 8: Neurocritical Care
8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury
9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies
9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy
10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition
10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral
11 Chapter 11: Quality, Safety, and Clinical Guidelines
11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions
12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine
12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management
13 Chapter 13: Treatment Planning and Care Coordination
13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education
1.2 Respiratory Failure and ARDS Pathophysiology
Key Takeaways Explain This Topic AI
Respiratory failure is primarily classified into Type I (hypoxemic, failure of oxygenation) and Type II (hypercapnic, failure of ventilation).
ARDS is a severe form of acute hypoxemic respiratory failure characterized by non-cardiogenic pulmonary edema driven by intense inflammation and increased alveolar-capillary permeability.
The pathophysiology of ARDS progresses through three phases: exudative (marked by protein-rich edema and alveolar collapse), proliferative (tissue repair and cellular infiltration), and fibrotic (collagen deposition and distorted lung architecture).
The Berlin Definition diagnoses ARDS based on timing, bilateral imaging opacities, exclusion of pure cardiogenic edema, and the degree of oxygenation deficit (PaO2/FiO2 ratio).
Management of ARDS relies on lung-protective ventilation, featuring low tidal volumes (6 mL/kg PBW) and adequate PEEP to minimize ventilator-induced lung injury (VILI).
Last updated: July 2026
Pathophysiology of Respiratory Failure
Acute respiratory failure is the inability of the respiratory system to adequately perform gas exchange, leading to hypoxemia, hypercapnia, or both. It is a defining feature of critical illness and a primary reason for admission to the intensive care unit (ICU). Respiratory failure is broadly classified into four types, with Types I and II being the most common in the medical ICU.
- Types of Respiratory Failure
- Type I: Hypoxemic Respiratory Failure
Type I respiratory failure is characterized by a failure of oxygenation, defined by an arterial oxygen tension (PaO2) of less than 60 mmHg on room air, with a normal or low arterial carbon dioxide tension (PaCO2). The fundamental pathophysiologic mechanisms underlying hypoxemia include:
Ventilation/Perfusion (V/Q) Mismatch: This is the most common cause. It occurs when areas of the lung are perfused but inadequately ventilated (e.g., pneumonia, pulmonary edema) or ventilated but inadequately perfused (e.g., pulmonary embolism).
Intrapulmonary Shunting: An extreme form of V/Q mismatch where blood flows through the pulmonary capillaries without participating in gas exchange because the alveoli are completely collapsed or fluid-filled. Shunts do not correct completely with supplemental oxygen.
Diffusion Limitation: A thickening of the alveolar-capillary membrane impairs oxygen transfer, typically seen in interstitial lung diseases, particularly during exercise.
Alveolar Hypoventilation: Reduced minute ventilation leads to a drop in alveolar PAO2, though this typically presents as Type II failure first.
Type II: Hypercapnic Respiratory Failure
Type II respiratory failure is characterized by a failure of ventilation, defined by a PaCO2 greater than 50 mmHg alongside acidemia (pH < 7.35). It occurs when alveolar ventilation is insufficient to clear the carbon dioxide produced by cellular metabolism. Causes include:
Central Drive Depression: Sedative overdoses or brainstem injury.
Neuromuscular Weakness: Guillain-Barré syndrome, myasthenia gravis, or critical illness polyneuropathy.
Increased Airway Resistance/Dead Space: COPD exacerbations or severe asthma, where the work of breathing exceeds the capacity of the respiratory muscles.
Type III and Type IV
Type III represents perioperative respiratory failure often due to atelectasis. Type IV relates to shock or hypoperfusion, where the respiratory muscles fail due to inadequate oxygen delivery and overwhelming cardiovascular demands.
Acute Respiratory Distress Syndrome (ARDS)
ARDS is a life-threatening form of severe, acute, hypoxemic respiratory failure caused by non-cardiogenic pulmonary edema. It represents a common pathway of lung injury from a variety of pulmonary (e.g., pneumonia, aspiration) or extrapulmonary (e.g., sepsis, severe trauma, pancreatitis) insults.
The Exudative Phase (Days 1-7)
The pathophysiology of ARDS begins with an intense inflammatory response within the lung tissue.
Endothelial and Epithelial Injury: The initial insult damages both the alveolar epithelium and the pulmonary capillary endothelium.
Loss of Barrier Function: The destruction of the alveolar-capillary barrier drastically increases permeability.
Protein-Rich Edema: Protein-rich fluid, neutrophils, and red blood cells flood the interstitial spaces and the alveoli. This widespread pulmonary edema is distinct from cardiogenic edema because it is driven by inflammation and permeability, not by elevated hydrostatic pressures.
Surfactant Dysfunction: Type II pneumocytes are damaged, leading to reduced surfactant production and the inactivation of existing surfactant by the proteinaceous fluid. This causes massive alveolar collapse (atelectasis), profound intrapulmonary shunting, and a severe drop in lung compliance ("stiff lungs").
During the exudative phase, patients exhibit profound hypoxemia that is highly resistant to supplemental oxygen due to the significant shunt fraction.
The Proliferative Phase (Days 7-21)
This phase represents an attempt at tissue repair. It is characterized by the proliferation of Type II pneumocytes (which attempt to replace the damaged Type I cells and restore surfactant) and the infiltration of fibroblasts. The edema begins to resorb, and the cellular exudate starts to clear. Some patients recover rapidly during this phase, while others progress to the final stage.
The Fibrotic Phase (Beyond Day 21)
A subset of patients fails to resolve the inflammation and instead develops extensive pulmonary fibrosis. The architecture of the lung is distorted by collagen deposition, leading to chronically reduced compliance, increased dead space, and persistent hypoxemia. Pulmonary hypertension frequently develops due to the obliteration of the pulmonary microvasculature.
Clinical Recognition and the Berlin Definition
ARDS is diagnosed clinically using the Berlin Definition, which requires the presence of four criteria:
Timing: Onset within 1 week of a known clinical insult or new/worsening respiratory symptoms.
Imaging: Bilateral opacities on chest radiograph or CT scan that cannot be fully explained by effusions, lobar/lung collapse, or nodules.
Origin of Edema: Respiratory failure not fully explained by cardiac failure or fluid overload (objective assessment like echocardiography is required if no obvious risk factor is present).
Oxygenation Deficit: Based on the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2 ratio), with a PEEP of ≥ \ge ≥ 5 cm H2O.
- Mild ARDS: PaO2/FiO2 201 - 300 mmHg
- Moderate ARDS: PaO2/FiO2 101 - 200 mmHg
- Severe ARDS: PaO2/FiO2 ≤ \le ≤ 100 mmHg
- Principles of Management
The management of ARDS centers on treating the underlying cause, providing supportive care, and employing lung-protective ventilation strategies to prevent ventilator-induced lung injury (VILI). Key principles include using low tidal volumes (6 mL/kg predicted body weight) to avoid volutrauma, utilizing Positive End-Expiratory Pressure (PEEP) to prevent alveolar collapse (atelectrauma) and improve oxygenation, and targeting lower plateau pressures ( ≤ \le ≤ 30 cm H2O) to prevent barotrauma. In severe cases, prone positioning and neuromuscular blockade are utilized to optimize V/Q matching and reduce oxygen consumption.